2 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow BRAF Gene Mutation: new trials by email Literature Review of BRAF Gene Mutation trials Research Report on BRAF Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies S241656, FOLFOX6/FOLFOX7, FOLFIRI - Non-small Cell Lung Cancer, Histiocytic Neoplasm | Phase 1 / Phase 2 | Recruiting | Institut de Recherches Internationales Servier | 554 | 2023-04-18 | 2026-10-13 |
| Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations Ulixertinib, Physician's Choice - Advanced Solid Tumor, BRAF Gene Mutation | Phase 2 | Terminated | BioMed Valley Discoveries, Inc | 104 | 2021-01-07 | 2024-06-04 |
| Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer Dabrafenib, Trametinib - Anaplastic Thyroid Cancer, Thyroid Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2020-01-20 | 2026-07-06 |
| Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor) - Melanoma (Skin), Melanoma Stage IIIb-IVM1a | Phase 2 | Withdrawn | TriHealth Inc. | 2019-06-24 | 2020-10-19 | |
| Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma Dabrafenib, Trametinib - Ameloblastoma, BRAF Gene Mutation | Phase 2 | Completed | Stanford University | 1 | 2017-07-17 | 2024-01-30 |
| Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein - ALK Gene Mutation, BRAF Gene Mutation | Phase 2 | Completed | University of Southern California | 42 | 2017-03-10 | 2025-10-22 |
Carcinoma, Non-Small-Cell Lung (2) · Thyroid Neoplasms (2) · Adamantinoma (1) · Ameloblastoma (1) · Brain Neoplasms (1) · Colorectal Neoplasms (1) · Histiocytosis (1) · Lung Neoplasms (1) · Melanoma (1) · Skin Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Thyroid Carcinoma, Anaplastic (1)
Neoplasms (5) · Neoplasms by Site (5) · Neoplasms by Histologic Type (4) · Head and Neck Neoplasms (3) · Bronchial Neoplasms (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Lung Diseases (2) · Neoplasms, Glandular and Epithelial (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Thyroid Diseases (2)
dabrafenib (3) · trametinib (3) · 130-nm albumin-bound paclitaxel (1) · Cetuximab (1) · Gemcitabine (1) · IFL protocol (1) · Panitumumab (1) · pembrolizumab (1) · talimogene laherparepvec (1) · ulixertinib (1)
BioMed Valley Discoveries, Inc (1) · Institut de Recherches Internationales Servier (1) · Memorial Sloan Kettering Cancer Center (1) · Stanford University (1) · TriHealth Inc. (1) · University of Southern California (1)
United States (6) · Australia (1) · China (1) · Denmark (1) · France (1) · Hong Kong (1) · Italy (1) · Japan (1) · Spain (1) · United Kingdom (1)
Alexander Colevas (1) · Eric Sherman, MD (1) · Jorge Nieva, MD (1)
2025 (1), P30CA014089 (1)